Q: What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.
Description: The Compound can be represented with the SMILES CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1.
Answer: Approved
{#Question|Q!}: {quest#}
{#Constraint:|Description:|!} The {#Molecule|Compound|Chemical!} {#has the|can be represented with the!} {SMILES__description} {SMILES#}.
{#Answer|Result|Answer!}: {answ#}
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1
3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid
What is the highest development stage achieved for this compound across all indications? Please respond with Approved, Phase 3 Clinical Trials, Phase 2 Clinical Trials, Phase 1 Clinical Trials, Early Phase 1 Clinical Trials, or Clinical Phase Unknown.